NASDAQ
IPSC

Century Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Century Therapeutics Inc Stock Price

Vitals

Today's Low:
$2.3
Today's High:
$2.4671
Open Price:
$2.43
52W Low:
$2.28
52W High:
$11.95
Prev. Close:
$2.36
Volume:
48031

Company Statistics

Market Cap.:
$147.62 million
Book Value:
4.174
Revenue TTM:
$4.56 million
Operating Margin TTM:
-2804.16%
Gross Profit TTM:
$5.20 million
Profit Margin:
0%
Return on Assets TTM:
-16.84%
Return on Equity TTM:
-41.94%

Company Profile

Century Therapeutics Inc had its IPO on 2021-06-18 under the ticker symbol IPSC.

The company operates in the Healthcare sector and Biotechnology industry. Century Therapeutics Inc has a staff strength of 163 employees.

Stock update

Shares of Century Therapeutics Inc opened at $2.43 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.3 - $2.47, and closed at $2.33.

This is a -1.27% slip from the previous day's closing price.

A total volume of 48,031 shares were traded at the close of the day’s session.

In the last one week, shares of Century Therapeutics Inc have slipped by -5.67%.

Century Therapeutics Inc's Key Ratios

Century Therapeutics Inc has a market cap of $147.62 million, indicating a price to book ratio of 1.5109 and a price to sales ratio of 102.4926.

In the last 12-months Century Therapeutics Inc’s revenue was $4.56 million with a gross profit of $5.20 million and an EBITDA of $-116228000. The EBITDA ratio measures Century Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Century Therapeutics Inc’s operating margin was -2804.16% while its return on assets stood at -16.84% with a return of equity of -41.94%.

In Q2, Century Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 92.9%.

Century Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-2.17 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Century Therapeutics Inc’s profitability.

Century Therapeutics Inc stock is trading at a EV to sales ratio of 40.6871 and a EV to EBITDA ratio of -1.5907. Its price to sales ratio in the trailing 12-months stood at 102.4926.

Century Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$417.16 million
Total Liabilities
$19.16 million
Operating Cash Flow
$6.97 million
Capital Expenditure
$4.50 million
Dividend Payout Ratio
0%

Century Therapeutics Inc ended 2024 with $417.16 million in total assets and $0 in total liabilities. Its intangible assets were valued at $417.16 million while shareholder equity stood at $247.57 million.

Century Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $19.16 million in other current liabilities, 6000.00 in common stock, $-583652000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $64.44 million and cash and short-term investments were $156.40 million. The company’s total short-term debt was $1,183,000 while long-term debt stood at $0.

Century Therapeutics Inc’s total current assets stands at $161.28 million while long-term investments were $144.58 million and short-term investments were $91.96 million. Its net receivables were $1.71 million compared to accounts payable of $3.63 million and inventory worth $-1706000.00.

In 2024, Century Therapeutics Inc's operating cash flow was $6.97 million while its capital expenditure stood at $4.50 million.

Comparatively, Century Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$2.33
52-Week High
$11.95
52-Week Low
$2.28
Analyst Target Price
$18.3

Century Therapeutics Inc stock is currently trading at $2.33 per share. It touched a 52-week high of $11.95 and a 52-week low of $11.95. Analysts tracking the stock have a 12-month average target price of $18.3.

Its 50-day moving average was $2.79 and 200-day moving average was $4.13 The short ratio stood at 12.81 indicating a short percent outstanding of 0%.

Around 3770.2% of the company’s stock are held by insiders while 5321.5% are held by institutions.

Frequently Asked Questions About Century Therapeutics Inc

The stock symbol (also called stock or share ticker) of Century Therapeutics Inc is IPSC

The IPO of Century Therapeutics Inc took place on 2021-06-18

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$51.33
-5.42
-9.55%
Hero MotoCorp Limited (HEROMOTOCO)
$3020.5
-32.25
-1.06%
$32.86
0.48
+1.48%
$0.22
0.01
+2.8%
$2.8
0
0%
$201.8
-1.7
-0.84%
$2.62
0.02
+0.77%
$306.1
-10.85
-3.42%
$5.39
0.41
+8.23%
$0.5
0.05
+12.18%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company’s lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-102, a CAR-iT targeting CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-107, an iPSC-derived Nectin-4 CAR gamma delta T-cell therapy product candidate; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Address

3675 Market Street, Philadelphia, PA, United States, 19104